GET DAILY SIGNALSHinge Health (HNGE) Delivers Strong Q3 2026 Results with Margin Expansion
Key Takeaways
- HNGE reported third quarter 2026 revenue of $235 million, up 52% year over year and above Wall Street expectations.
- Adjusted earnings per share (EPS) reached $0.71, beating consensus estimates as the company delivered another beat-and-raise quarter.
- Non-GAAP operating margin expanded to 33%, up from 20% a year earlier, reflecting strong operating leverage.
- Last-twelve-months (LTM) calculated billings rose 54% to $960.3 million, a key leading indicator of future revenue momentum.
- Full-year 2026 revenue guidance was raised to $879–$881 million, marking the third consecutive upward revision this year.
- For more on Hinge Health's latest developments, visit Major News, Today's Price Move, Price Targets, and Forecast pages.
- Discover new trading ideas by exploring Trending AI Robots.
Earnings Context and Why It Matters
Hinge Health, a San Francisco–based digital health company focused on musculoskeletal (MSK) care, has become one of 2026's standout performers, with its stock rallying strongly through the year. The third quarter 2026 report, released after the market close on November 2, 2026, matters because it tests whether the company can sustain its rapid revenue growth while expanding margins and deepening enterprise adoption. After consecutive beat-and-raise quarters, investors are watching closely to see whether management's momentum in billings, client count, and yield remains durable. The results offer a fresh signal on demand across employer and health-plan customers and on the company's broader push into adjacent areas such as migraine and gastrointestinal care. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, Hinge Health reported revenue of $235 million, an increase of 52% year over year and above the roughly $224.8 million consensus estimate compiled by FactSet. Adjusted (non-GAAP) EPS came in at $0.71, exceeding the $0.58 FactSet consensus. On a GAAP basis, diluted EPS swung to $0.66, compared with a $0.02 loss per share in the prior-year quarter.
Non-GAAP operating income reached $77.2 million, up 154% year over year and well above management's own guidance of $61 million to $63 million. Non-GAAP operating margin expanded to 33%, up from 20% a year earlier and 29% in the prior quarter. Gross margin improved to 88% from 83% a year ago. LTM calculated billings rose 54% to $960.3 million, while total clients grew 28% year over year to 3,270.
Management raised its full-year 2026 revenue outlook to a range of $879 million to $881 million, up from $856 million to $860 million previously, implying roughly 50% growth at the midpoint. Full-year non-GAAP operating income guidance was also lifted to $266 million to $268 million, implying an operating margin of about 30%.
Market Reaction and Investor Sentiment
Hinge Health shares advanced modestly in extended trading following the third quarter 2026 report, reflecting a mixed but generally constructive reception. The company cleared published consensus estimates, yet the stock had already climbed sharply ahead of the print, leaving limited room for a strong post-earnings surge. Sentiment remains largely positive, driven by accelerating billings, expanding margins, and a third straight upward revision to full-year guidance. Still, some investors noted that the implied fourth-quarter growth rate steps down from recent quarters and that average selling prices are expected to remain roughly flat through 2027. The market appears to be weighing strong operational execution against an already elevated valuation.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will focus on whether Hinge Health can sustain its yield improvements, which management has described as structural rather than one-time tailwinds. The company's enrollment campaigns, member renewals, and referrals have driven stronger engagement, and continued progress here is central to the growth story.
Another key factor is the multi-product strategy. Hinge Health is expanding beyond MSK care into migraine and gastrointestinal (GI) offerings, including its recently announced Cylinder Health acquisition. Adoption across these newer product lines will be an important catalyst as integrated offerings scale through 2027.
Margin durability also warrants attention. Management is holding to an approximately 85% gross margin target for 2027 even after printing 88% in the latest quarter, signaling planned reinvestment in care teams and infrastructure. Finally, investors should watch billings growth and client retention as early indicators of future revenue, alongside any updates on the fourth-quarter trajectory and 2027 outlook. From what I see, these elements will shape how the story unfolds in the months ahead.
Exploring AI Tools for Stock Analysis
In my own workflow, Tickeron’s AI Screener has become a practical resource for filtering opportunities across sectors like digital health. It lets users apply technical patterns, fundamentals, and AI-driven signals to scan thousands of stocks and ETFs efficiently. For names like HNGE, this kind of tool helps surface comparable setups and momentum candidates without manual effort, supporting a more informed view of the broader landscape.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HNGE's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for HNGE turned positive on October 01, 2026. Looking at past instances where HNGE's MACD turned positive, the stock continued to rise in 10 of 10 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 29, 2026. You may want to consider a long position or call options on HNGE as a result. In 21 of 24 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
Following a +2.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where HNGE advanced for three days, in 79 of 93 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Aroon Indicator entered an Uptrend today. In 61 of 70 cases where HNGE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
Bearish Trend Analysis
The 10-day RSI Indicator for HNGE moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 8 similar instances where the indicator moved out of overbought territory. In 4 of the 8 cases, the stock moved lower in the following days. This puts the odds of a move lower at 50%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HNGE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
HNGE broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 25 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. HNGE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: HNGE's P/B Ratio (27.063) is slightly higher than the industry average of (4.699). P/E Ratio (13.981) is within average values for comparable stocks, (13.248). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (10.504) is also within normal values, averaging (6.065).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HNGE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement